Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
| Autor: | Eric J. Yang, Tina Bhutani, Bridget Myers, Vidhatha Reddy |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Halobetasol Propionate business.industry Therapeutic effect Dermatology medicine.disease Topical medication Clinical trial 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Tazarotene 030220 oncology & carcinogenesis Psoriasis Lotion Pharmacodynamics Medicine business medicine.drug |
| Zdroj: | Clinical, Cosmetic and Investigational Dermatology. 13:391-398 |
| ISSN: | 1178-7015 |
| DOI: | 10.2147/ccid.s252426 |
| Popis: | Halobetasol propionate and tazarotene lotion 0.01%/0.045% (HP/TAZ) is a topical medication approved for the treatment of plaque psoriasis in adults. As a treatment modality, HP/TAZ has a combinatory therapeutic effect because it contains both a corticosteroid (HP) and a retinoid (TAZ) component. Here, we review the important clinical efficacy and safety data derived from pivotal clinical trials for HP/TAZ in the treatment of plaque psoriasis. We also discuss the mechanism of action, dosage guidelines, pharmacokinetics/pharmacodynamics, and clinical considerations for HP/TAZ, including why HP/TAZ should be avoided in pregnant patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|